Current Vaccine Trials in Glioblastoma: A Review

Table 2

EGFRvIII vaccine trials.

Trial name	Phase	𝑁	Experimental design	PFS (mo)	OS (mo)	References
VICTORI	I	12	Vaccine administered 60% sensitized	10.2	22.8	[16, 17]
ACTIVATE	II	19	Vaccine + GM-CSF versus case matched controls	12	47.7 in sensitized pts; 22.8 in nonsensitized pts	NCT00643097 [20]
ACT II	II	22	Vaccine + high dose short course TMZ versus low dose prolonged course TMZ. Improved immune sensitization in patients with prolonged TMZ treatment	15.2	23.6	[21]
ACT III	II	65	Vaccine + GM-CSF + TMZ versus TMZ	12.3	24.6	NCT00458601 [19]
ACT IV	III		Vaccine + GM-CSF + TMZ versus TMZ and placebo alone	Ongoing	Ongoing	NCT01480479
ReACT	II		Relapsed GBM, vaccine + GM-CSF + bevacizumab versus bevacizumab	Ongoing	Ongoing	NCT01498328
Pediatric pontine glioma pilot study	I		Children with DIPG vaccine + GM-CSF after radiation	Ongoing	Ongoing	NCT01058850

𝑁: number of patients; PFS: progression-free survival; OS: overall survival.